A Lipid Prodrug Strategy Enhances Targeted Protein Degrader CNS Pharmacokinetics
- 5 August 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17339-17349
Abstract
Targeted protein degraders that recruit the von Hippel–Lindau E3-ligase complex often have poor physicochemical properties, requiring extensive medicinal chemistry optimization prior to use in hypothesis-testing experiments in vivo and with few blood–brain barrier permeable examples disclosed. In this study, we systematically examine a panel of fatty acid promoieties as agents to enhance degrader pharmacokinetics and BBB-exposure. We characterize effects on cellular E3-ligase engagement, cellular BRD4 degradation kinetics, murine plasma stability, and murine blood plasma and brain pharmacokinetics and pharmacodynamics. We identify degrader prodrugs with significantly improved CNS exposure relative to the parent degrader. This led to successful BRD4 degradation in perfused brain samples, demonstrating that fatty acid promoieties can accelerate progress toward proof of principle in vivo experiments for CNS degrader projects.Keywords
All Related Versions
Funding Information
- National Institute of Neurological Disorders and Stroke (DP2NS132610)
- University of California, San Diego
- Pharmaceutical Research and Manufacturers of America Foundation (30149761)
- American Chemical Society
- National Institute of General Medical Sciences (T32GM139795)
This publication has 16 references indexed in Scilit:
- Chemical Specification of E3 Ubiquitin Ligase Engagement by Cysteine-Reactive ChemistryJournal of the American Chemical Society, 2023
- PROTAC targeted protein degraders: the past is prologueNature Reviews Drug Discovery, 2022
- A High-Throughput Method to Prioritize PROTAC Intracellular Target Engagement and Cell Permeability Using NanoBRET2021
- First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivoEuropean Journal of Medicinal Chemistry, 2021
- Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection IntervalsCNS Spectrums, 2020
- Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspectiveDrug Discovery Today, 2020
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4ACS Chemical Biology, 2020
- Sobetirome prodrug esters with enhanced blood–brain barrier permeabilityBioorganic & Medicinal Chemistry, 2016
- Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophreniaSchizophrenia Research, 2014
- Biological conversion of aripiprazole lauroxil − An N-acyloxymethyl aripiprazole prodrugResults in Pharma Sciences, 2014